The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.L'invention concerne une méthode pour réduire la charge de traitement pour des patients qui présentent un trouble néovasculaire intraoculaire, la méthode comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste de VEGF selon une posologie qui comprend des intervalles de traitement de 8 et/ou 12 semaines.
